Author:
Zhao Hongli,Sun Guoxun,Kong Desheng,Zhang Yujing,Shi Wudan,Zhao Mingming,Hong Luojia,Qiao Zhenkui
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology,General Medicine
Reference35 articles.
1. El Helw LM, Lorigan PC, Robinson MH, Coleman RE, Hancock BW. VEDex (vincristine, epirubicin, dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin’s lymphoma. Int J Oncol. 2000;16:777–82.
2. Shamash J, Lee SM, Radford JA, et al. Patterns of relapse and subsequent management following high dose chemotherapy with autologus haematopoietic supporting relapsed or refractory Hodgkin’s lymphoma: a two centre study. Ann Oncol. 2000;11(6):715–9.
3. Zhu HH, Wu DP, Jin J, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment ofacute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol. 2013;31(33):4215–21.
4. Huang BT, Zeng QC, Gurung A, Zhao WH, Xiao Z, Li BS. The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience. Med Oncol. 2012;29(3):2088–94.
5. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–21.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献